Sort
85,873 grants matching “alzheimers”
Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging population
$1,676,951Eliezer Masliah · National Institute On Aging · ZIA · FY2019 · AG
Alzheimer's Disease Prevention Trial with Estrogens
$1,676,632Mount Sinai School Of Medicine Of Nyu · R01 · FY2003 · AG
University of Kansas Alzheimer's Disease Core Centers
$1,676,155Russell H Swerdlow · University Of Kansas Medical Center · P30 · FY2016 · AG
Alzheimer variants: Propagation of shared functional changes across cellular networks
$1,676,096Philip L De Jager · Columbia University Health Sciences · U01 · FY2021 · AG
Dissecting the impact of senescence on microglia function and neurodegeneration
$1,675,000Dorothy Patricia Schafer · Univ Of Massachusetts Med Sch Worcester · RF1 · FY2020 · AG
The UCSF Brain Health Assessment for the Detection of Cognitive Impairment Among Diverse Populations in Primary Care
$1,674,583Katherine Laurel Possin · University Of California, San Francisco · UH3 · FY2020 · NS
Community Engagement, Recruitment and Retention (CERR) Core D
$1,674,254Zhao Chen · University Of Arizona · U19 · FY2021 · AG
Establishing cellular-validated standards for parcellating hippocampal subfields in aging and Alzheimer's disease
$1,673,865Jean Augustinack · Massachusetts General Hospital · RF1 · FY2021 · AG
High Capacity, High Performance Storage System for Neuroscience
$1,673,615Arthur W Toga · University Of Southern California · S10 · FY2022 · OD
Contributions of stress reactivity to risk of Alzheimer's disease and related dementia's in a community-based cohort
$1,673,246Kiarri N Kershaw · Northwestern University At Chicago · R01 · FY2021 · AG
Washington University Center for Translational Neuroscience
$1,673,178David M Holtzman · Washington University · P30 · FY2007 · NS
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
$1,672,856Michael G Agadjanyan · Institute For Molecular Medicine · U01 · FY2021 · AG
Emerging Role of Tau Citrullination During Alzheimerâs disease and Tauopathies
$1,672,789Daniel Carl Lee · University Of Kentucky · RF1 · FY2021 · AG
Translational Evaluation of PET Radiotracers
$1,672,749Robert Innis · National Institute Of Mental Health · ZIA · FY2019 · MH
Polarity dysregulation in Alzheimerâs disease
$1,671,360Huaye Zhang · Rutgers Biomedical And Health Sciences · RF1 · FY2024 · NS
The Importance of Abnormal Inflammasome Activation as a Risk Factor between Traumatic Brain Injury and Alzheimerâs Disease
$1,671,321W. Dalton Dalton Dietrich · University Of Miami School Of Medicine · RF1 · FY2023 · NS
Aging Well, Sleeping Efficiently: Intervention Studies
$1,670,848Timothy H. Monk · University Of Pittsburgh At Pittsburgh · P01 · FY2006 · AG
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT
$1,670,656Davangere P Devanand · Columbia University Health Sciences · R01 · FY2025 · AG
Indiana Alzheimer Disease Center
$1,670,201Bernardino Ghetti · Indiana University Indianapolis · P30 · FY2009 · AG
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)
$1,670,170Susan Cheng · Cedars-Sinai Medical Center · U54 · FY2021 · AG
Multi-omic functional assessment of novel AD variants using high-throughput and single-cell technologies
$1,669,192Thomas J Montine · Stanford University · U01 · FY2022 · AG
Clinical evaluation of BMS-984923 metabolism.
$1,669,100Timothy R Siegert · Allyx Therapeutics Inc. · SB1 · FY2025 · AG
MULTICENTER VITAMIN E TRIAL-PERSONS WITH DOWN SYNDROME
$1,668,552Institute For Basic Res In Dev Disabil · R01 · FY2004 · AG
PHASE II/III trial for Slowing Progression in Mild Cognitive Impairment
$1,668,503Michela Gallagher · Johns Hopkins University · R01 · FY2016 · AG
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets
$1,668,072Philip L De Jager · Columbia University Health Sciences · U01 · FY2018 · AG